Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation
This study aimed to evaluate the efficacy and safety of venetoclax plus azacitidine and donor lymphocyte infusion (DLI) in treating patients with relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Twenty-six AML patients who relapsed after all...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2022-01, Vol.101 (1), p.119-130 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 130 |
|---|---|
| container_issue | 1 |
| container_start_page | 119 |
| container_title | Annals of hematology |
| container_volume | 101 |
| creator | Zhao, Peng Ni, Ming Ma, Dan Fang, Qin Zhang, Yan Li, Yanju Huang, Yi Chen, Ying Chai, Xiao Zhan, Yun Li, Yan Kang, Qian Zhao, Mei Liu, Min Zhang, Fengqi Huang, Shisi Wen, Shuangshuang Deng, Bo Wang, Jishi |
| description | This study aimed to evaluate the efficacy and safety of venetoclax plus azacitidine and donor lymphocyte infusion (DLI) in treating patients with relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Twenty-six AML patients who relapsed after allo-HSCT were enrolled and treated with venetoclax plus azacitidine and DLI. Complete remission with incomplete recovery (CRi), partial remission (PR), and objective remission rate (ORR) were assessed, and then event-free survival (EFS) and overall survival (OS) were evaluated. Besides, adverse events were documented. Additionally, whole exome sequencing was performed in bone marrow samples. The CRi, PR, and ORR rates were 26.9%, 34.6%, and 61.5%, respectively. The median time of EFS and OS was 120 (95% CI: 71–610) days and 284.5 (95% CI: 81–610) days, respectively. The most common adverse events were hematologic system adverse events including agranulocytosis, anemia, and thrombocytopenia, while the adverse events of other systems were relatively less and milder. In addition, no serious adverse events existed. Of note, there were 6 (23.1%) patients who developed GVHD. As for gene mutation, 49 mutated genes were found, which were categorized as first-, second-, and third-class mutations, and then further analysis revealed that the first-class mutations were not correlated with EFS or OS. Additionally, the most frequent mutated genes were FLT3, CEBPA, DNMT3A, KIT, KRAS, and NRAS. Venetoclax plus azacitidine and DLI is efficient and tolerant in treating patients with relapsed AML after allo-HSCT, implying this combined therapy as a potential treatment option in the studied patients. |
| doi_str_mv | 10.1007/s00277-021-04674-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8720738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2615862807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-ab3e45e00cc5cd5efe96073d6e45b64422b465635c2c96f34c4855c66fc330263</originalsourceid><addsrcrecordid>eNp9UsuO1DAQjBCIHQZ-gAOyxIVLwPEryQUJrVhAWokLcLU8TmfGi2MH24GZ_SS-kh5mWR4HfPGjqqtd6qqqxw193lDavsiUsratKWtqKlQr6v2datUIzmoqO3G3WtGe97XEdVY9yPmK0oZ1gt2vzriQqutbvqq-f4IAJVpv9mT2Sybm2lhX3OACEBMGMsQQE_GHad5FeyhAXBiX7GLAAykJTHFhS4xdEJoO4KMbiIflM0zOkBlRCCWTb7tIEngzZ1QdCyRivI9b7O0s2cFkSpyjg4K3XGAiFrxHdRPy7E0oKBPDw-reaHyGRzf7uvp48frD-dv68v2bd-evLmsrWlFqs-EgJFBqrbSDhBF6RVs-KHzdKCEY2wglFZeW2V6NXFjRSWmVGi3nlCm-rl6edOdlM8Fg0UAyXs_JTSYddDRO_40Et9Pb-FV3LcNGHQo8uxFI8csCuejJ5aMjEyAuWTPVKNbjcBqkPv2HehWXFNDekSU7xTqUXFfsxLIp5pxgvP1MQ_UxCvoUBY1R0D-joPdY9ORPG7clv2aPBH4iZITCFtLv3v-R_QFywMXI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2615862807</pqid></control><display><type>article</type><title>Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Zhao, Peng ; Ni, Ming ; Ma, Dan ; Fang, Qin ; Zhang, Yan ; Li, Yanju ; Huang, Yi ; Chen, Ying ; Chai, Xiao ; Zhan, Yun ; Li, Yan ; Kang, Qian ; Zhao, Mei ; Liu, Min ; Zhang, Fengqi ; Huang, Shisi ; Wen, Shuangshuang ; Deng, Bo ; Wang, Jishi</creator><creatorcontrib>Zhao, Peng ; Ni, Ming ; Ma, Dan ; Fang, Qin ; Zhang, Yan ; Li, Yanju ; Huang, Yi ; Chen, Ying ; Chai, Xiao ; Zhan, Yun ; Li, Yan ; Kang, Qian ; Zhao, Mei ; Liu, Min ; Zhang, Fengqi ; Huang, Shisi ; Wen, Shuangshuang ; Deng, Bo ; Wang, Jishi</creatorcontrib><description>This study aimed to evaluate the efficacy and safety of venetoclax plus azacitidine and donor lymphocyte infusion (DLI) in treating patients with relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Twenty-six AML patients who relapsed after allo-HSCT were enrolled and treated with venetoclax plus azacitidine and DLI. Complete remission with incomplete recovery (CRi), partial remission (PR), and objective remission rate (ORR) were assessed, and then event-free survival (EFS) and overall survival (OS) were evaluated. Besides, adverse events were documented. Additionally, whole exome sequencing was performed in bone marrow samples. The CRi, PR, and ORR rates were 26.9%, 34.6%, and 61.5%, respectively. The median time of EFS and OS was 120 (95% CI: 71–610) days and 284.5 (95% CI: 81–610) days, respectively. The most common adverse events were hematologic system adverse events including agranulocytosis, anemia, and thrombocytopenia, while the adverse events of other systems were relatively less and milder. In addition, no serious adverse events existed. Of note, there were 6 (23.1%) patients who developed GVHD. As for gene mutation, 49 mutated genes were found, which were categorized as first-, second-, and third-class mutations, and then further analysis revealed that the first-class mutations were not correlated with EFS or OS. Additionally, the most frequent mutated genes were FLT3, CEBPA, DNMT3A, KIT, KRAS, and NRAS. Venetoclax plus azacitidine and DLI is efficient and tolerant in treating patients with relapsed AML after allo-HSCT, implying this combined therapy as a potential treatment option in the studied patients.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-021-04674-x</identifier><identifier>PMID: 34568973</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Azacitidine - therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use ; Female ; Follow-Up Studies ; Hematology ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia ; Leukemia, Myeloid, Acute - therapy ; Lymphocyte Transfusion ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation ; Neoplasm Recurrence, Local - therapy ; Oncology ; Original ; Original Article ; Remission (Medicine) ; Stem cell transplantation ; Sulfonamides - therapeutic use ; Transplantation, Homologous ; Treatment Outcome ; Young Adult</subject><ispartof>Annals of hematology, 2022-01, Vol.101 (1), p.119-130</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-ab3e45e00cc5cd5efe96073d6e45b64422b465635c2c96f34c4855c66fc330263</citedby><cites>FETCH-LOGICAL-c474t-ab3e45e00cc5cd5efe96073d6e45b64422b465635c2c96f34c4855c66fc330263</cites><orcidid>0000-0002-4412-2283</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-021-04674-x$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-021-04674-x$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34568973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Peng</creatorcontrib><creatorcontrib>Ni, Ming</creatorcontrib><creatorcontrib>Ma, Dan</creatorcontrib><creatorcontrib>Fang, Qin</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Li, Yanju</creatorcontrib><creatorcontrib>Huang, Yi</creatorcontrib><creatorcontrib>Chen, Ying</creatorcontrib><creatorcontrib>Chai, Xiao</creatorcontrib><creatorcontrib>Zhan, Yun</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Kang, Qian</creatorcontrib><creatorcontrib>Zhao, Mei</creatorcontrib><creatorcontrib>Liu, Min</creatorcontrib><creatorcontrib>Zhang, Fengqi</creatorcontrib><creatorcontrib>Huang, Shisi</creatorcontrib><creatorcontrib>Wen, Shuangshuang</creatorcontrib><creatorcontrib>Deng, Bo</creatorcontrib><creatorcontrib>Wang, Jishi</creatorcontrib><title>Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>This study aimed to evaluate the efficacy and safety of venetoclax plus azacitidine and donor lymphocyte infusion (DLI) in treating patients with relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Twenty-six AML patients who relapsed after allo-HSCT were enrolled and treated with venetoclax plus azacitidine and DLI. Complete remission with incomplete recovery (CRi), partial remission (PR), and objective remission rate (ORR) were assessed, and then event-free survival (EFS) and overall survival (OS) were evaluated. Besides, adverse events were documented. Additionally, whole exome sequencing was performed in bone marrow samples. The CRi, PR, and ORR rates were 26.9%, 34.6%, and 61.5%, respectively. The median time of EFS and OS was 120 (95% CI: 71–610) days and 284.5 (95% CI: 81–610) days, respectively. The most common adverse events were hematologic system adverse events including agranulocytosis, anemia, and thrombocytopenia, while the adverse events of other systems were relatively less and milder. In addition, no serious adverse events existed. Of note, there were 6 (23.1%) patients who developed GVHD. As for gene mutation, 49 mutated genes were found, which were categorized as first-, second-, and third-class mutations, and then further analysis revealed that the first-class mutations were not correlated with EFS or OS. Additionally, the most frequent mutated genes were FLT3, CEBPA, DNMT3A, KIT, KRAS, and NRAS. Venetoclax plus azacitidine and DLI is efficient and tolerant in treating patients with relapsed AML after allo-HSCT, implying this combined therapy as a potential treatment option in the studied patients.</description><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Azacitidine - therapeutic use</subject><subject>Bridged Bicyclo Compounds, Heterocyclic - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Lymphocyte Transfusion</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Remission (Medicine)</subject><subject>Stem cell transplantation</subject><subject>Sulfonamides - therapeutic use</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9UsuO1DAQjBCIHQZ-gAOyxIVLwPEryQUJrVhAWokLcLU8TmfGi2MH24GZ_SS-kh5mWR4HfPGjqqtd6qqqxw193lDavsiUsratKWtqKlQr6v2datUIzmoqO3G3WtGe97XEdVY9yPmK0oZ1gt2vzriQqutbvqq-f4IAJVpv9mT2Sybm2lhX3OACEBMGMsQQE_GHad5FeyhAXBiX7GLAAykJTHFhS4xdEJoO4KMbiIflM0zOkBlRCCWTb7tIEngzZ1QdCyRivI9b7O0s2cFkSpyjg4K3XGAiFrxHdRPy7E0oKBPDw-reaHyGRzf7uvp48frD-dv68v2bd-evLmsrWlFqs-EgJFBqrbSDhBF6RVs-KHzdKCEY2wglFZeW2V6NXFjRSWmVGi3nlCm-rl6edOdlM8Fg0UAyXs_JTSYddDRO_40Et9Pb-FV3LcNGHQo8uxFI8csCuejJ5aMjEyAuWTPVKNbjcBqkPv2HehWXFNDekSU7xTqUXFfsxLIp5pxgvP1MQ_UxCvoUBY1R0D-joPdY9ORPG7clv2aPBH4iZITCFtLv3v-R_QFywMXI</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Zhao, Peng</creator><creator>Ni, Ming</creator><creator>Ma, Dan</creator><creator>Fang, Qin</creator><creator>Zhang, Yan</creator><creator>Li, Yanju</creator><creator>Huang, Yi</creator><creator>Chen, Ying</creator><creator>Chai, Xiao</creator><creator>Zhan, Yun</creator><creator>Li, Yan</creator><creator>Kang, Qian</creator><creator>Zhao, Mei</creator><creator>Liu, Min</creator><creator>Zhang, Fengqi</creator><creator>Huang, Shisi</creator><creator>Wen, Shuangshuang</creator><creator>Deng, Bo</creator><creator>Wang, Jishi</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4412-2283</orcidid></search><sort><creationdate>20220101</creationdate><title>Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation</title><author>Zhao, Peng ; Ni, Ming ; Ma, Dan ; Fang, Qin ; Zhang, Yan ; Li, Yanju ; Huang, Yi ; Chen, Ying ; Chai, Xiao ; Zhan, Yun ; Li, Yan ; Kang, Qian ; Zhao, Mei ; Liu, Min ; Zhang, Fengqi ; Huang, Shisi ; Wen, Shuangshuang ; Deng, Bo ; Wang, Jishi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-ab3e45e00cc5cd5efe96073d6e45b64422b465635c2c96f34c4855c66fc330263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Azacitidine - therapeutic use</topic><topic>Bridged Bicyclo Compounds, Heterocyclic - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Lymphocyte Transfusion</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Remission (Medicine)</topic><topic>Stem cell transplantation</topic><topic>Sulfonamides - therapeutic use</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Peng</creatorcontrib><creatorcontrib>Ni, Ming</creatorcontrib><creatorcontrib>Ma, Dan</creatorcontrib><creatorcontrib>Fang, Qin</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Li, Yanju</creatorcontrib><creatorcontrib>Huang, Yi</creatorcontrib><creatorcontrib>Chen, Ying</creatorcontrib><creatorcontrib>Chai, Xiao</creatorcontrib><creatorcontrib>Zhan, Yun</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Kang, Qian</creatorcontrib><creatorcontrib>Zhao, Mei</creatorcontrib><creatorcontrib>Liu, Min</creatorcontrib><creatorcontrib>Zhang, Fengqi</creatorcontrib><creatorcontrib>Huang, Shisi</creatorcontrib><creatorcontrib>Wen, Shuangshuang</creatorcontrib><creatorcontrib>Deng, Bo</creatorcontrib><creatorcontrib>Wang, Jishi</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Peng</au><au>Ni, Ming</au><au>Ma, Dan</au><au>Fang, Qin</au><au>Zhang, Yan</au><au>Li, Yanju</au><au>Huang, Yi</au><au>Chen, Ying</au><au>Chai, Xiao</au><au>Zhan, Yun</au><au>Li, Yan</au><au>Kang, Qian</au><au>Zhao, Mei</au><au>Liu, Min</au><au>Zhang, Fengqi</au><au>Huang, Shisi</au><au>Wen, Shuangshuang</au><au>Deng, Bo</au><au>Wang, Jishi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>101</volume><issue>1</issue><spage>119</spage><epage>130</epage><pages>119-130</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>This study aimed to evaluate the efficacy and safety of venetoclax plus azacitidine and donor lymphocyte infusion (DLI) in treating patients with relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Twenty-six AML patients who relapsed after allo-HSCT were enrolled and treated with venetoclax plus azacitidine and DLI. Complete remission with incomplete recovery (CRi), partial remission (PR), and objective remission rate (ORR) were assessed, and then event-free survival (EFS) and overall survival (OS) were evaluated. Besides, adverse events were documented. Additionally, whole exome sequencing was performed in bone marrow samples. The CRi, PR, and ORR rates were 26.9%, 34.6%, and 61.5%, respectively. The median time of EFS and OS was 120 (95% CI: 71–610) days and 284.5 (95% CI: 81–610) days, respectively. The most common adverse events were hematologic system adverse events including agranulocytosis, anemia, and thrombocytopenia, while the adverse events of other systems were relatively less and milder. In addition, no serious adverse events existed. Of note, there were 6 (23.1%) patients who developed GVHD. As for gene mutation, 49 mutated genes were found, which were categorized as first-, second-, and third-class mutations, and then further analysis revealed that the first-class mutations were not correlated with EFS or OS. Additionally, the most frequent mutated genes were FLT3, CEBPA, DNMT3A, KIT, KRAS, and NRAS. Venetoclax plus azacitidine and DLI is efficient and tolerant in treating patients with relapsed AML after allo-HSCT, implying this combined therapy as a potential treatment option in the studied patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34568973</pmid><doi>10.1007/s00277-021-04674-x</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-4412-2283</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2022-01, Vol.101 (1), p.119-130 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8720738 |
| source | MEDLINE; SpringerLink (Online service) |
| subjects | Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Azacitidine - therapeutic use Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Female Follow-Up Studies Hematology Hematopoietic Stem Cell Transplantation Humans Leukemia Leukemia, Myeloid, Acute - therapy Lymphocyte Transfusion Male Medicine Medicine & Public Health Middle Aged Mutation Neoplasm Recurrence, Local - therapy Oncology Original Original Article Remission (Medicine) Stem cell transplantation Sulfonamides - therapeutic use Transplantation, Homologous Treatment Outcome Young Adult |
| title | Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T16%3A09%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Venetoclax%20plus%20azacitidine%20and%20donor%20lymphocyte%20infusion%20in%20treating%20acute%20myeloid%20leukemia%20patients%20who%20relapse%20after%20allogeneic%20hematopoietic%20stem%20cell%20transplantation&rft.jtitle=Annals%20of%20hematology&rft.au=Zhao,%20Peng&rft.date=2022-01-01&rft.volume=101&rft.issue=1&rft.spage=119&rft.epage=130&rft.pages=119-130&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-021-04674-x&rft_dat=%3Cproquest_pubme%3E2615862807%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2615862807&rft_id=info:pmid/34568973&rfr_iscdi=true |